Species level identification of
microorganisms is vital in combating the vast range of pathogens that
infect humans. Bacteria, yeast and mycobacteria, whether clinically
common or rare, can cause serious harm when not identified and treated
quickly. Increasingly prevalent conditions, such as sepsis or multi-drug
resistant (MDR) microorganism infections, pose a serious threat to
hospitals and wider public health, requiring rapid, automated microbial
identification and resistance testing solutions for the entire clinical
workflow.
In parallel, effective hygiene management – especially in hospitals – is key to prevent healthcare associated infections as effectively as possible.
Bruker’s MALDI Biotyper®
system has become the method of choice for routine microorganism
identification in clinical laboratories worldwide. Based on
Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight mass
spectrometry (MALDI-TOF MS) technology, this microbial identification
system is easy-to-use, fast, robust, high-throughput, cost-effective and
highly efficient. Molecular diagnostics are another rapid solution for
clinical microbiology, enabling real-time results in a culture-free
workflow, for example in the case of fungal infections. Bruker’s
expertise in antimicrobial susceptibility testing (AST) and mycobacteria
identification provides a complete solution, continuously innovating to
address today’s global diseases.